Evidence map›Paper›PMID 39022781›Full record

ArticleIJTLD open2024

Prevalence, incidence and determinants of QuantiFERON

J Stewart, N Walker, K Jennings, C Delport, J Nuttall, A K Coussens, R Dyers, D A Jolliffe, J C Y Tang, W D Fraser and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

J StewartDesmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa.
N WalkerWolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
K JenningsHealth Department, Cape Town Municipality, Cape Town.
C DelportDesmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa.
J NuttallPaediatric Infectious Diseases Unit, Red Cross War Memorial Children's Hospital, Cape Town.
A K CoussensInfectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
R DyersWestern Cape Government: Health and Wellness, Cape Town.
D A JolliffeBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London.
J C Y TangNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich.
W D FraserNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich.
R J WilkinsonCentre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town.
L-G BekkerDesmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa.
A R MartineauBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London.
K MiddelkoopDesmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTB control requires the understanding and disruption of TB transmission. We describe prevalence, incidence and risk factors associated with childhood TB infection in Cape Town, South Africa.

methodsWe report cross-sectional baseline and prospective incidence data from a large trial among primary school children living in high TB burden communities. Prevalent infection was defined as QuantiFERON™-TB Gold Plus (QFT-Plus) positivity as assessed at baseline. Subsequent conversion to QFT-Plus positivity was measured 3 years later among those QFT-Plus-negative at baseline. Multivariable logistic regression models examined factors associated with TB infection.

resultsQuantiFERON-positivity at baseline (prevalence: 22.6%, 95% CI 20.9-24.4), was independently associated with increasing age (aOR 1.24 per additional year, 95% CI 1.15-1.34) and household exposure to TB during the participant's lifetime (aOR 1.87, 95% CI 1.46-2.40). QFT-Plus conversion at year 3 (12.2%, 95% CI 10.5-14.0; annual infection rate: 3.95%) was associated with household exposure to an index TB case (aOR 2.74, 95% CI 1.05-7.18).

conclusionRates of QFT-diagnosed TB infection remain high in this population. The strong association with household TB exposure reinforces the importance of contact tracing, preventative treatment and early treatment of infectious disease to reduce community transmission.

Indexed as

IGRAlatent TBpaediatricQFT-Plus

Identifiers

PMID39022781
PMCPMC11249604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.